Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

4.355 +0.225 (+5.45%)
Streaming Delayed Price Updated: 10:21 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics Inc

< Previous 1 2 3 4 5 Next >
G1 Therapeutics Announces Pricing of Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
G1 Therapeutics Announces Proposed Public Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug
Via Benzinga
G1 Therapeutics: Q3 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
G1 Therapeutics Return On Capital Employed Insights
  
Via Benzinga
G1 Therapeutics: Q2 Earnings Insights
  G1 Therapeutics (NASDAQ:GTHX) reported its Q2 earnings results on Wednesday, August 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. 
Via Benzinga
G1 Therapeutics: Q1 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings For G1 Therapeutics
Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy - 
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
From G1 Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities
WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
G1 Therapeutics: Q4 Earnings Insights
G1 Therapeutics (NASDAQ:GTHX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 06:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021
Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ: 
Via Benzinga
G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript
GTHX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: G1 Therapeutics Q3 Earnings
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
22 Stocks Moving in Friday's Pre-Market Session
Gainers LM Funding America, Inc. (NASDAQ: LMFA) rose 39.5% to $4.80 in pre-market trading after declining around 15% on Thursday. The company recently announced it purchased an... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Jefferies raised Perrigo Company plc (NYSE:PRGO) pr... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Return on Capital Employed Overview: G1 Therapeutics
Pulled from Benzinga Pro data G1 Therapeutics (NASDAQ:GTHX) reported Q2 sales of $6.60 million. Earnings fell to a loss of $38.19 million, resulting in a 49.57% decrease from last... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.